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Recent advances in avian transgenesis have led to the possibility of
utilizing the laying hen as a production platform for the large-scale
synthesis of pharmaceutical proteins. Ovalbumin constitutes more
than half of the protein in the white of a laid egg, and expression
of the ovalbumin gene is restricted to the tubular gland cells of the
oviduct. Here we describe the use of lentiviral vectors to deliver
transgene constructs comprising regulatory sequences from the
ovalbumin gene designed to direct synthesis of associated thera-
peutic proteins to the oviduct. We report the generation of trans-
genic hens that synthesize functional recombinant pharmaceutical
protein in a tightly regulated tissue-specific manner, without any
evidence of transgene silencing after germ-line transmission.
chicken  genetic modification  lentivirus  pharmaceutical
Many human therapeutic proteins, such as monoclonalantibodies, are produced in industrial bioreactors, but
setting up such systems is both time-consuming and expensive.
Increasing global demand for recombinant pharmaceutical pro-
teins has resulted in significant research being focused on
development of alternative production platforms, including the
use of transgenic animals as bioreactors. The basic strategy used
has been to target expression of a therapeutic protein to a
protein secretory tissue, often the mammary gland, using the
regulatory sequences of one of the native proteins synthesized in
that tissue. The production of therapeutic proteins has now been
demonstrated in transgenic mammals, including sheep, goats,
cattle, rabbits (1, 2), and chickens (3–5). The use of transgenic
chickens as bioreactors to synthesize therapeutic proteins, as a
component of egg yolk or white, may have several advantages
over mammalian expression systems, including a shorter time-
scale for setup and ease of scaleup to a transgenic flock, lower
costs associated with husbandry, the potential to produce pro-
teins that are toxic to mammalian cells, beneficial glycosylation
profile, and reduced immunogenicity of the purified product
(reviewed in ref. 6).
The first reported attempt to generate transgenic hens ex-
pressing a therapeutic protein used a vector derived from the
avian retrovirus avian leukosis virus, but injection of a low-titer
vector preparation into the subgerminal cavity of embryos from
new-laid eggs proved to be very inefficient (3). Injection of a
high-titer retroviral vector derived from mouse stem cell virus
into the heart of embryos that had been incubated for 55 h
resulted in both efficient transgenesis and recombinant protein
synthesis, but suppression of transgene expression was observed
after germ-line transmission (4). This phenomenon would be
problematic for effective scaleup. Recent reports have described
the culturing and genetic modification of chicken ES cells (ref.
5) or primordial germ cells (ref. 7), which were used to generate
chickens that were chimeras between the modified cells and
wild-type recipients. High levels of somatic chimerism with
chicken ES cells and germ-line contribution by primordial germ
cells were demonstrated, but the fidelity of oviduct-specific
expression of a human monoclonal antibody in chicken ES cells
chimeras was variable. We have shown that lentiviral vectors can
be used to generate germ-line transgenic chickens with high
efficiency (8), and tissue-specific expression of a transgene
delivered using a lentiviral vector has been demonstrated in
quail (9).
In this work, we utilize lentiviral vectors derived from equine
infectious anemia virus (EIAV) to generate transgenic chickens.
This vector has been rendered multiply defective by deletion of
all viral coding sequences from the transfer genome. Vectors are
produced from separate expression plasmids that are designed to
minimize the potential for homologous recombination. The
transgenes investigated consist of codon-optimized sequences
for either a humanized ScFv-Fc miniantibody, known as miR24,
derived from a mouse monoclonal antibody shown to have
potential for the treatment of malignant melanoma (10), or
human IFN--1a (hIFN1a), expression of which is directed by
regulatory sequences from the chicken ovalbumin gene. Ovalbu-
min constitutes 54% of the protein in the white of hens’ eggs,
and the steroid-responsive tissue-specific regulation of the
ovalbumin gene is well documented (11). We describe the
generation of transgenic chickens that synthesize functional
recombinant therapeutic protein specifically in the oviduct of
laying hens as a component of egg white.
Results
Construct Design. The regulatory sequences of the ovalbumin
gene have been investigated in detail, although the minimum
sequence required for oviduct-restricted expression in vivo has
not been defined. The EIAV vectors we used to generate
transgenic chickens with high efficiency have a capacity of9 kb.
Regulatory sequences and parts of the exon/intron structure of
the gene were used to generate the following constructs: the
construct designated OVA contained the steroid-dependent
regulatory element, the negative regulatory element, exon 1,
intron 1, and the beginning of exon 2 (OVA, 2.8 kb). The
estrogen-responsive enhancer element (ERE) was cloned im-
mediately 5 to the steroid-dependent regulatory element to
generate construct EREOVA (3.5 kb). The endogenous Kozak
and start codon were deleted during PCR amplification and
replaced with a unique restriction endonuclease site to facilitate
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frame-independent insertion. A Kozak consensus sequence and
start codon were included in the synthetic constructs for the two
target proteins. The target proteins were a chimeric ScFv-Fc
miniantibody (miR24) and hIFN1a. The coding sequence for
miR24 was cloned adjacent to the OVA sequence, and the
coding sequence for hIFN1a was cloned adjacent to both OVA
and EREOVA sequences (Fig. 1). The vectors were packaged
and injected into embryos from new-laid eggs to generate G0
transgenic birds.
Production and Analysis of Transgenic Birds. A single G0 cockerel
(bird OR2-4), hatched after injection of OVA-miR24 vector, was
estimated to have vector sequence present in the germ line at a
frequency of 5%, by PCR analysis of genomic DNA from semen
samples. OR2-4 was crossed to stock hens and 463 chicks
screened, among which 19 (4%) transgenic G1 offspring were
identified. Genomic DNA from these G1 birds was analyzed by
restriction digestion and Southern blot analysis to determine the
number of vector insertions in each bird and the number of
different insertion events represented in the G1 generation.
Genomic DNA digested with HindIII generated junction frag-
ments that revealed that two independent vector insertions were
present in these G1 birds (Fig. 2Ai). No G1 birds were found that
carried both proviral insertions. SpeI digestion to release a
fragment spanning the ovalbumin regulatory sequence and
transgene generated the predicted fragment of 5.2 kb in all cases,
indicating that the ovalbumin intron present in the vector was
retained in the transgenic chickens (data from the first 10 chicks
are shown; Fig. 2Aii).
A single G0 cockerel (bird OI2-4) transduced with OVA-IFN
vector and three G0 cockerels (birds EOI2-6, EOI3-11, and
EOI3-13) transduced with EREOVA-IFN vector were crossed
to stock hens to generate G1 chicks. Genomic DNA was isolated
from two G1 birds carrying the OVA-IFN vector and 12 G1 birds
carrying the EREOVA-IFN vector. For Southern transfer anal-
ysis, genomic DNA was digested with NcoI to generate junction
fragments (Fig. 2Bi) or NcoI/NdeI to release a fragment span-
ning the ovalbumin regulatory sequence and transgene (Fig.
2Bii). The two OVA-IFN birds represented unique vector
insertion events (Fig. 2Bi, lanes 10 and 11), and each contained
an intact transgene as evidenced by a 3.3-kb internal fragment
(Fig. 2Bii). The 12 EREOVA-IFN birds represented a total of
nine independent vector-insertion events. An identical insertion
was shared by two offspring of EOI3-13 (Fig. 2Bi, lanes 1 and 6)
and another by all three offspring of EOI3-11 (Fig. 2Bi, lanes
12–14). After double digestion, DNA from 9 of the 12 birds
produced a fragment of 4.4 kb (Fig. 2Bii), indicating an intact
transgene. A truncated fragment of 1.2 kb was detected in the
three remaining birds, corresponding to a splicing event during
production of the vector between a strong cryptic splice donor
in the ERE sequence and the splice acceptor site of exon 2. This
splicing event was confirmed by PCR, cloning, and sequence
analysis of these samples (data not shown).
Transgene Expression Is Restricted to the Oviduct. We aimed to
direct transgene expression to the oviduct of laying hens by
utilizing regulatory sequences of the ovalbumin gene to control
expression of the two therapeutic proteins. Tissue samples were
collected from oviduct, pancreas, brain, intestine, liver, heart,
and breast muscle of adult G1 and G2 hemizygous transgenic
Fig. 1. Schematic representation of the structure of the vectors described
after chromosomal integration. Relative positions of lentiviral elements (light
gray) and ovalbumin regulatory sequences (dark gray) are indicated, including
the EIAV LTRs and packaging signal () and the ovalbumin gene ERE; steroid-
dependent regulatory element (SDRE), negative regulatory element (NRE),
exon 1, intron 1, and the 5 segment of exon 2 of the ovalbumin transcribed
sequence; and the Kozak sequence and coding sequence of either miR24 or
hIFN1a (CDS). The positions of restriction sites SpeI (S), NcoI (Nc), HindIII (H),
and NdeI (Nd) used in restriction analysis are marked. The U3 region of the 3
LTR is modified such that the integrated provirus lacks an active promoter
within the LTR. Relative positions of regulatory elements in the chicken
ovalbumin locus are shown.
Fig. 2. Southern transfer analysis of genomic DNA from individual G1 birds.
(A and B) Samples from 10 birds carrying the OVA-miR24 provirus (A) were
digested with HindIII (Ai) or SpeI (Aii) to generate either a junction fragment
or a fragment spanning the ovalbumin regulatory sequence, respectively.
Samples from two birds carrying the OVA-IFN provirus and 12 birds carrying
the EREOVA-IFN provirus (B) were digested with NcoI (Bi) or NcoI/NdeI (Bii) to
generate either a junction fragment or a fragment spanning the ovalbumin
regulatory sequence, respectively. The G0 sires of the G1-IFN birds analyzed are
indicated below.
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hens that were in lay to assess whether transgene expression was
restricted to the oviduct of adult hens. Northern blot analysis of
total RNA extracted from these tissues was carried out on
samples from two G1 and two G2 hens carrying the OVA-miR24
transgene, two G2 hens carrying the EREOVA-IFN transgene,
and a nontransgenic control hen. Transcripts for bothmiR24 and
hIFN1a were limited to the magnum region of the oviduct (Fig.
3), as was the endogenous ovalbumin transcript. RT-PCR on
samples from one of the G2 hens carrying the OVA-miR24
transgene confirmed that the miR24 transcript was restricted to
the magnum [supporting information (SI) Fig. 7]. To investigate
the site of synthesis of miR24 in more detail, immunohistochem-
istry on magnum sections with a FITC-conjugated anti-human
IgG (Fc-specific) was performed (Fig. 4). These data demon-
strate that miR24 protein was localized to tubular gland cells and
absent in adjoining epithelial cells. Taken together, these data
show that the 2.8- and 3.5-kb 5 regulatory sequences from the
ovalbumin gene utilized in the current study are sufficient to
confer tissue-specific expression of transgenes delivered using a
lentiviral vector.
Recombinant Proteins Are Secreted into Egg White. The amount of
recombinant protein produced per egg was analyzed by measuring
the proteins in a series of eggs laid by individual transgenic birds.
Eggs laid by transgenic G1 and G2 hens were collected and the egg
white assayed by ELISA for the presence of recombinant protein.
Each of the first 20 eggs and then every 10th subsequent egg
from each hen was analyzed (up to a maximum of the 150th egg).
Recombinant protein was detected in the egg white of all
eggs assayed (Fig. 5), and levels remained consistent in eggs from
each bird over time. Eggs from nine hens containing the OVA-
miR24 vector (5  G1 and 4  G2) and representing both
independent vector insertions were assayed. The mean values for
recombinant miR24 were between 15 and 50 g/ml (Fig. 5A). EggsFig. 3. Northern blot analysis of total RNA from individual G1 and G2 hens.
(A–D) Total RNA was extracted from the magnum portion of the oviduct (M),
spleen (S), pancreas (P), brain (B), intestine (I), liver (L), and breast muscle (Br)
from: two G1 hens (OR2-4:447 and OR2-4:476,A) and two G2 hens (OR2-4:25:59
and OR2-4:25:171,B) carrying the OVA-miR24 vector; two G2 hens carrying the
EREOVA-IFN vector (EOI3-13:148:14 and EOI3-13:148:40, C), and a nontrans-
genic control hen (D). Blots were sequentially hybridized with probes for
either miR24 (R) or hIFN1a (I), followed by an ovalbumin probe (O) and then
18S ribosomal RNA (18S), with the exception of the control, which was
hybridized sequentially with probes for miR24, hIFN1a, ovalbumin, and 18S
ribosomal RNA.
Fig. 4. Immunohistochemical detection of miR24 in oviduct sections. (A and
B) Sections of the magnum portion of the oviduct of hen OR2-4:25:59 (A) and
a nontransgenic control (B) were stained with the nuclear stain Hoescht to
visualize individual cells or FITC-anti-human IgG to visualize location of miR24.
Tubular gland cells expressing the transgene appear green, whereas epithelial
cells lining the tubular glands (indicated by arrows) do not produce miR24.
Fig. 5. Concentration of recombinant protein in egg white from transgenic
hens. (A and B) Egg-white solution was assayed by ELISA for the presence of
recombinant miR24 (A) or hIFN1a (B). Columns represent the mean concen-
tration of recombinant protein (SD) in egg white from each of the first 20
eggs and then each subsequent 10th egg up to a maximum of the 150th egg
from the hens indicated. G1 and G2 hens are indicated above, with individual
bird numbers below.
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froma singleG1 hen containing theOVA-IFNvector, togetherwith
three G1 and two G2 hens containing EREOVA-IFN vector, were
also assayed. Themean values for recombinant hIFN1a protein in
eggs from these six hens were more variable than observed for the
miR24, ranging from 3.5 to 426 g/ml (Fig. 5B). Eggs from hen
OI2–4:380 (OVA-IFN) contained hIFN1a at a mean value of 38
g/ml, falling within the rangemeasured in eggs from hens with the
EREOVA-IFN vector.
Recombinant hIFN1a in Egg White Is Functional. Egg white from
hens carrying the hIFN1a transgenes was analyzed to deter-
mine whether the recombinant protein synthesized was func-
tional. Eggs from a hen carrying the OVA-IFN vector (OI2-
4:380) and from two hens carrying the EREOVA-IFN vector
(EOI2-6:328 and EOI3-13:813) were collected and egg white
assayed for the presence of active hIFN1a by using a standard
antiviral/cytopathic effect assay. VeroE6 cells were incubated
with dilutions of egg white collected from eggs from the trans-
genic hens, then infected with Semliki Forest Virus. After
incubation, the degree to which the egg white and positive
control recombinant hIFN1a protected cells from infection and
subsequent cytolysis was assessed. Egg white from all eggs from
transgenic hens demonstrated antiviral activity in this cytopathic
effect assay (Fig. 6), but no protection was seen by using control
egg white from stock hen eggs. The concentrations of hIFN1a
present in eggs, as determined by ELISA, correlated with
protective activity, as determined by this assay, with the egg from
hen EOI2-6:328 containing the highest amount of active
hIFN1a and the egg from hen EOI3-13:813 containing the
lowest amount. These data demonstrate the functional equiva-
lence of recombinant hIFN1a between different transgenic
birds.
Discussion
We previously reported that lentiviral vectors can be utilized for
the efficient production of transgenic chickens (8). Multiple lines
of transgenic birds were generated, and stable transmission of
integrated vector through the germ line was demonstrated with
a conserved transgene expression profile in G1 and G2 genera-
tions. In the present work, we have progressed this application
of EIAV-derived lentiviral vectors to demonstrate tissue-specific
expression of heterologous proteins in the oviduct of laying hens,
using transgenes derived from regulatory sequences from the
chicken ovalbumin gene locus.
The chicken ovalbumin gene encodes more than half of egg
white protein, 2.2 g of protein per egg (12), with up to 105
copies of the ovalbumin mRNA per cell in the oviduct of laying
hens (13). A previous report (5) utilized either 7.5 or 15 kb of the
ovalbumin 5 regulatory sequence coupled with 15 kb of 3
sequence in an attempt to direct transgene expression specifi-
cally to the tubular gland cells of the magnum of laying hens.
These constructs were transfected into chicken ES cells and the
modified cells used to generate chimeric hens whose oviduct
tissue was in part derived from the transgenic chicken ES cells.
RT-PCR analysis of RNA from these chimeric hens revealed
expression of the ovalbumin-derived transgene in the magnum of
the oviduct, but expression was also detected in the intestine,
leading the authors (5) to hypothesize that the regulatory regions
utilized were not sufficient to obtain transgene expression
restricted to the oviduct in vivo.
The constructs investigated in the current study were sig-
nificantly shorter than those discussed above (5), with the
OVA construct spanning only 2.8 kb 5 to the translation start
site. In the EREOVA construct, a 675-bp fragment spanning
the ERE, normally located3.3 kb 5 to the transcription start
site (20), was cloned directly 5 to the end of the OVA
construct. Northern blot analysis of mRNA extracted from a
range of tissues of transgenic hens in lay showed that tran-
scripts from either transgene were restricted to the magnum
portion of the oviduct, coincident with ovalbumin expression.
Ectopic expression was not detected in any of the tissues
analyzed. Additionally, immunohistochemical staining of sec-
tions of the magnum revealed that recombinant protein syn-
thesis was restricted to the region containing the tubular gland
cells, the site of ovalbumin synthesis in the magnum, and was
absent from adjacent epithelial cells. This observation of
tissue-specific transgene expression, using a lentiviral vector to
deliver the transgene, is consistent with previous reports from
mouse (14), pig (15), quail (9), and rat (16).
The ERE region, included in the EREOVA construct, con-
tains four half-palindromic binding sites for the estrogen recep-
tor that have been shown to act synergistically in vitro, and it was
anticipated that inclusion of this element might enhance the
quantity of recombinant protein synthesized by transgenic hens.
Surprisingly, comparison of eggs from a hen (OI2-4:380) carry-
ing the OVA-IFN transgene with those from hens carrying the
EREOVA-IFN transgene (EOI3-13:813 and EOI3-11:649) re-
vealed that the inclusion of this element did not result in an
increase in the mean level of hIFN1a protein in egg white in the
birds analyzed. The exception to this observation was hen
EOI2-6:328, where the mean hIFN1a protein level in eggs was
2-fold higher than in eggs from other birds carrying the same
construct. Because the number of transgenic hens analyzed is
limited, it is not possible to draw any firm conclusions about
influence of the different ovalbumin regulatory elements on
transgene expression levels from these data. Additional factors,
such as the vector integration site, the genetic background of the
hens, and epigenetic factors, are likely to influence the expres-
sion level of any specific transgene integrant. For example,
variation in recombinant protein expression level in different
hens containing the same vector integration site has been
reported (3). It is unlikely that the observed variations in
expression level would be an impediment to commercialization
when averaged over a production flock.
In recent years, several incremental advances have been made in
the use of retroviral vectors for avian transgenesis. Replication
Fig. 6. Biological activity of recombinant hIFN1a in egg white from trans-
genic hens. Egg white from hens OI2-4:380, EOI2-6:328, and EOI3-13:813 was
analyzed in a cytopathic effect assay for antiviral activity. By applying a
nonlinear regression (curve fit), the dilution of each sample, which resulted in
50% of cells being protected from Semliki forest virus (EC50), was calculated
and compared with the EC50 for reference IFN1a to determine hIFN1a
concentration (activity) in the egg white samples. Estimates of hIFN1a mea-
sured by ELISA in the same egg white samples are provided for comparison.
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defective avian leukosis virus was used to generate hens expressing
the reporter -lactamase from a ubiquitous promoter. While -
lactamasewas detected in eggwhite of transgenic hens, the quantity
of protein, efficiency of transgenesis, and germ-line transmission
rate were all low (17, 18). Arian leukosis virus was also used to
generate chickens expressing human IFN--2b at higher levels than
had been reported for-lactamase (3), but the efficiencywithwhich
transgenic birds were generated remained very low (a single G1
cockerel from 1,597 chicks hatched), presumably a consequence of
the low-titer vector used. Blastodermal injection of high-titerMolo-
ney murine leukemia virus-derived vectors was used to generate
transgenic quail with very high efficiency, but transgene silencing
prevented detectable expression of the reporter GFP (19). A
modifiedmouse stem cell virus injected into the heart of developing
chick embryos generated transgenic hens that expressed an an-
tiprion protein ScFv-Fc from a ubiquitous promoter, but analysis of
G0, G1, andG2 generations revealed2-fold transgene suppression
in successive generations (4). Although we observed no evidence of
transgene silencing, continued assessment of transgene expression
levels will bemade for several generations to confirm the long-term
stability of expression required for commercial protein production.
A lentiviral vector was previously used to generate transgenic quail
that showed tissue-specific expression without any evidence of
ectopic expression or transgene silencing between generations (9).
The current report demonstrates the combination of efficient
generation of transgenic hens with the synthesis of functional
therapeutic proteins at high levels in the egg white.
Methods
Plasmid Construction. Chimeric mouse–human ScFv-Fc minianti-
body miR24 and hIFN1a coding sequences were modified to
reflect the codon bias in the chicken and to include the signal
peptide from chicken lysozyme at the 5 end. The miR24 coding
sequence, synthesized by Entelechon (Regensburg, Germany),
was PCR-amplified to introduce SmaI and PmlI flanking re-
striction endonuclease sites and then cloned into pGEMTeasy
(Promega, Madison, WI) to generate pLE11. hIFN1a sequence
including SmaI flanking restriction endonuclease sites was syn-
thesized by Geneart (Regensburg, Germany) and supplied in
PCR-Script (Stratagene, La Jolla, CA).
Primers 5DHR2 (5-CTTAAGTCCTCAGACTTGGC-3)
and 3Sma (5-GCCCCGGGTGAACTCTGAGTTGTCTAG-
3) were designed to amplify a 2.8-kb fragment 5 to the coding
sequence of chicken ovalbumin gene. The PCR product was
cloned into pGEMTeasy to generate plasmid pLE10 (OVA
promoter). Primers LD675for (5-CTGCAGAAAAATGC-
CAGGTGG-3) and LD675rev (5-TCTAGAGAGAGTAAG-
CAACAATCTTCT-3) were designed to amplify a 675-bp
region spanning the ERE, a DNaseI hypersensitivity site3.3 kb
5 to the ovalbumin transcription start site (20). The PCR
product was cloned into pGEMTeasy to generate plasmid
pLE20a. pLE10 was linearized at the extreme 5 end of its
ovalbumin regulatory sequence with NcoI, and blunt ends were
generated with T4 DNA polymerase. The ERE was excised from
pLE20a with EcoRI, and blunt ends were generated with T4
DNA polymerase and then ligated into pLE10 to give plasmid
pLE21 (EREOVA promoter).
miR24 was excised from pLE11 by SmaI/PmlI digestion and
subcloned into the SmaI site of pLE10 to give pRI38. The
promoter/transgene was excised from pRI38 by digestion with
SacII/MluI and subcloned into the SacII/AscI sites of the min-
imal EIAV lentiviral vector pONY8.45Nmcs to give pLE38
(OVA-miR24).
hIFN1a was subcloned into the SmaI site of pLE21 to give
pLE43. The promoter/transgene was excised from pLE43 by diges-
tion with AatII/MluI, and blunt ends were generated with T4 DNA
polymerase. pONY8.45Nmcs was digested with SacII/AscI, blunt
ends were generated with T4 DNA polymerase, and the promoter/
transgene above ligated in to give pLE46 (EREOVA-IFN).
The ERE sequence was excised from pLE43 by digestion with
AflII/AatI to generate plasmid pLE42. The promoter/transgene
from pLE42 was excised with ApaI/MluI, blunt ends were gener-
ated with T4 DNA polymerase, and the fragment was ligated into
pONY8.45Nmcs to give pLE45 (OVA-IFN). Schematic represen-
tation of integrated constructs is presented in Fig. 1.
Lentivirus Production. Vector stocks were generated by FuGene6
(Roche, Lewes, U.K.) transfection of HEK293T cells plated on
144-mm dishes with 10.2 g of vector plasmid/5.1 g of gag/pol
plasmid (pESYNGP)/2.5 g of rev plasmid (pESYNRev) (21)/
0.2 g of VSV-G plasmid (pRV67) (22). Forty-eight hours after
transfection, tissue culture medium was harvested and filtered
(0.22 m), then centrifuged at 6,000 g for 20 h at 4°C, followed
by ultracentrifugation at 50,500 g for 120min at 4°C. The pellet
was resuspended in formulation buffer (20 mM Tris/100 mM
NaCl/10 mg/ml sucrose/10 mg/ml mannitol, pH 7.4). Aliquots of
vector were stored at 80°C.
Production and Analysis of Transgenic Birds. Founder transgenic
birds were generated by injection of viral vectors into chick
embryos at the new-laid egg stage, followed by culture of the
embryos to hatch as described (8). The hatched chicks were
raised to sexual maturity, and DNA extracted from semen from
adult males was screened by PCR as described (8, 23) to identify
cockerels that carried vector sequences in the germ line. Cock-
erels identified by this method were crossed to wild-type hens,
and their offspring were screened by PCR to identify G1
hemizygous transgenic birds. All experiments, animal breeding,
and care procedures were carried out under license from the
U.K. Home Office.
The vector insertions in individual G1 birds were analyzed by
Southern transfer. Genomic DNA (10 g), extracted from whole
blood, was digested with appropriate restriction endonucleases,
resolved on a 0.7% wt/vol agarose gel, and transferred to
Hybond-N membrane (Amersham Biosciences, Chalfont St.
Giles, U.K.). These blots were analyzed by using probes labeled
with [32P]dCTP using a RediPrime II kit (Amersham Bio-
sciences). Hybridization was in 500 mM sodium phosphate (pH
7.2)/7% SDS at 65°C and was detected by autoradiography.
RNA and Protein Analysis. Tissue samples (50 mg) were ex-
tracted, snap-frozen, and stored at 80°C until required. Total
RNA was prepared by using RNA-Bee (AMS Biotech, Abing-
don, U.K.), and 10 g was resolved on a denaturing 1% wt/vol
agarose gel. RNA was transferred to Hybond-N membrane
(Amersham Biosciences) by using 10 SSC (1 SSC  0.15 M
sodium chloride/0.015 M sodium citrate, pH 7). Hybridization
was as for Southern blots.
To assay recombinant protein expressed in egg white, eggs
were carefully cracked open and the egg white was recovered
free of yolk. The egg white was mixed for at least 60 min at 4°C
with 4 vol of ice-cold 50 mM Na acetate buffer (pH 5.0) to
remove the bulk of the ovomucin fraction.
For detection of miR24 protein, Immulon 2B plates (Thermo
Labsystems, Basingstoke, U.K.) were coated with sheep anti-
human IgG (-chain specific, AU004; The Binding Site, Bir-
mingham, U.K.) antibody at a concentration of 4 g/ml 50 mM
carbonate/bicarbonate buffer (pH 9.6) and incubated for 1 h at
room temperature. The standard used was human IgG1 antibody
(BP078; The Binding Site). Plates were washed with PBS/0.05%
Tween 20 (PBST) before adsorbing sample egg white solution
(pH 5.5). Egg white samples were tested in duplicate and
incubated for 1 h at room temperature. Plates were washed with
PBST, and the presence of miR24 was revealed by horseradish
peroxidase-conjugated anti-sheep/goat IgG antibody at a dilu-
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tion of 1:1,000 in PBST for 1 h at room temperature (AP004; The
Binding Site). The plates were washed with PBST and incubated
for 5 min at room temperature with 0.4 mg/ml o-phenylenedi-
amine/0.006% hydrogen peroxide in 50 mM phosphate-citrate
buffer (pH 5.0). The reaction was stopped and developed by the
addition of 0.25 vol of 12.5% sulfuric acid. Plates were read at 490
nm, and data were analyzed by using a log:logit plot onMicrosoft
Excel (Microsoft, Redmond, WA). The sensitivity of the ELISA
was 8 ng/ml.
hIFN1a protein concentration in egg white was determined
by using a Human IFN- ELISA kit (PBL Biomedical Labora-
tories, Piscataway, NJ; product no. 41400-2A). Data were ana-
lyzed by using GraphPad (San Diego, CA) Prism software. The
sensitivity of this assay is 250 pg/ml.
Immunohistochemistry.Adult tissues were isolated and fixed for 30
min in 4% paraformaldehyde in PBS, and tissues were cryo-
embedded and sectioned at 14 m on Superfrost Plus micro-
scope slides (VWR, Lutterworth, U.K.). Slides were blocked in
PBST containing 10% heat-inactivated chicken serum for 1 h
and incubated for 1 h in secondary antibody solution (1:100
dilution of FITC-conjugated anti-human IgG; Sigma, St. Louis,
MO) PBST containing 10% chicken serum. Slides were washed
for 1 additional hour in PBST, counterstained with Hoechst, and
mounted.
Cytopathic Effect Assay. VeroE6 cells were seeded at a density of
1  104 into each well of a 96-well plate (200 l per well of
DMEM/10% FBS/1% penicillin/streptomycin/glutamine). Cells
were incubated at 37°C in 5% CO2 for 24 h. Medium was then
replaced with 100 l of DMEM/2% FBS/1% penicillin/
streptomycin/glutamine, except column 2, to which 150 l of
DMEM plus 2.66% FBS/1% penicillin/streptomycin/glutamine
was added. Fifty microliters of test egg white samples, undiluted
or prediluted 1:1,000 with serum-free medium, was added to
column 2.
As controls, Escherichia coli-derived IFN1a (PBL Biomed-
ical Laboratories) was spiked into egg white solution from a
control egg (undiluted or prediluted 1:1,000 serum-free me-
dium) or into SFM at 4,000 units/ml.
Samples and controls were serially diluted (2-fold) across the
96-well plates from columns 2 to 11. Column 1 was retained as
the untreated control, and column 12 was retained as the
uninfected control. Plates of cells were then incubated at 37°C
5% CO2 for 24 h before infection of each well in columns 1–11
with 150 plaque-forming units of Semliki Forest virus in 100 l.
Plates of cells were further incubated at 37°C 5% CO2 for 48 h,
and virus-induced cytolysis was assessed by using the lactate
dehydrogenase cytotoxicity kit (Roche), according to the man-
ufacturer’s instructions. Results were analyzed by using Graph-
Pad Prism to compare the titer EC50 for egg white samples with
the EC50 determined from a known concentration of E. coli-
produced hIFN1a.
Plasmids pLE21, pLE45, and pLE46 are available upon re-
quest from Viragen (Scotland) Ltd. Plasmids pESYNGP, pE-
SYNRev, and pRV67 are available upon request from Oxford
Biomedica Ltd.
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